Louise Davies1, H Gilbert Welch. 1. VA Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, Vermont 05009, USA. Louise.Davies@dartmouth.edu
Abstract
OBJECTIVE: To compare the survival rate of people with papillary thyroid cancer limited to the thyroid gland who have not had immediate, definitive treatment for their thyroid cancer with the survival rate of those who have had such treatment. DESIGN: Cohort study of incident cancer cases and initial treatment data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Data on cause of death was taken from the National Vital Statistics System. PATIENTS: Patients with papillary thyroid cancer limited to the thyroid gland. MAIN OUTCOME MEASURE: Cancer-specific survival. RESULTS: Of all eligible people in the data (n = 35,663), 1.2% did not undergo immediate, definitive treatment (n = 440). The life table estimate of their 20-year cancer-specific survival rate was 97% (95% confidence interval [CI], 96%-100%). The corresponding estimate for the patients who did receive treatment was 99% (95% CI, 93%-100%). Among those who did not receive immediate, definitive treatment, 6 died from their cancer. This number is not statistically different from the number of thyroid cancer deaths in the treated group over the same period (n = 161) (P = .09). CONCLUSION: Papillary thyroid cancers of any size that are limited to the thyroid gland (no extraglandular extension or lymph node metastases at presentation) have favorable outcomes whether or not they are treated in the first year after diagnosis and whether they are treated by hemithyroidectomy or total thyroidectomy.
OBJECTIVE: To compare the survival rate of people with papillary thyroid cancer limited to the thyroid gland who have not had immediate, definitive treatment for their thyroid cancer with the survival rate of those who have had such treatment. DESIGN: Cohort study of incident cancer cases and initial treatment data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Data on cause of death was taken from the National Vital Statistics System. PATIENTS: Patients with papillary thyroid cancer limited to the thyroid gland. MAIN OUTCOME MEASURE: Cancer-specific survival. RESULTS: Of all eligible people in the data (n = 35,663), 1.2% did not undergo immediate, definitive treatment (n = 440). The life table estimate of their 20-year cancer-specific survival rate was 97% (95% confidence interval [CI], 96%-100%). The corresponding estimate for the patients who did receive treatment was 99% (95% CI, 93%-100%). Among those who did not receive immediate, definitive treatment, 6 died from their cancer. This number is not statistically different from the number of thyroid cancer deaths in the treated group over the same period (n = 161) (P = .09). CONCLUSION:Papillary thyroid cancers of any size that are limited to the thyroid gland (no extraglandular extension or lymph node metastases at presentation) have favorable outcomes whether or not they are treated in the first year after diagnosis and whether they are treated by hemithyroidectomy or total thyroidectomy.
Authors: Benjamin D Hallowell; Meheret Endeshaw; Matthew T McKenna; Virginia Senkomago; Hilda Razzaghi; Mona Saraiya Journal: Prev Med Date: 2019-06-18 Impact factor: 4.018
Authors: Iain J Nixon; Laura Y Wang; Jocelyn C Migliacci; Antoine Eskander; Michael J Campbell; Ahmad Aniss; Lilah Morris; Fernanda Vaisman; Rossana Corbo; Denise Momesso; Mario Vaisman; Andre Carvalho; Diana Learoyd; William D Leslie; Richard W Nason; Deborah Kuk; Volkert Wreesmann; Luc Morris; Frank L Palmer; Ian Ganly; Snehal G Patel; Bhuvanesh Singh; R Michael Tuttle; Ashok R Shaha; Mithat Gönen; K Alok Pathak; Wen T Shen; Mark Sywak; Luis Kowalski; Jeremy Freeman; Nancy Perrier; Jatin P Shah Journal: Thyroid Date: 2016-02-25 Impact factor: 6.568
Authors: Kepal N Patel; Trevor E Angell; Joshua Babiarz; Neil M Barth; Thomas Blevins; Quan-Yang Duh; Ronald A Ghossein; R Mack Harrell; Jing Huang; Giulia C Kennedy; Su Yeon Kim; Richard T Kloos; Virginia A LiVolsi; Gregory W Randolph; Peter M Sadow; Michael H Shanik; Julie A Sosa; S Thomas Traweek; P Sean Walsh; Duncan Whitney; Michael W Yeh; Paul W Ladenson Journal: JAMA Surg Date: 2018-09-01 Impact factor: 14.766
Authors: Cláudia C D Nakabashi; Teresa S Kasamatsu; Felipe Crispim; Claudia A Yamazaki; Cléber P Camacho; Danielle M Andreoni; Rosalia P Padovani; Elza S Ikejiri; Maria C O M Mamone; Flávia C Aldighieri; Jairo Wagner; Jairo T Hidal; José G H Vieira; Rosa P M Biscolla; Rui M B Maciel Journal: Eur Thyroid J Date: 2014-03-12
Authors: Laura Y Wang; Benjamin R Roman; Jocelyn C Migliacci; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly Journal: Cancer Date: 2015-08-17 Impact factor: 6.860